ABBV vs. WFC: A Head-to-Head Stock Comparison

Updated on October 8, 2025

Here’s a clear look at ABBV and WFC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	ABBV	WFC
Company Name	AbbVie Inc.	Wells Fargo & Company
Country	United States	United States
GICS Sector	Health Care	Financials
GICS Industry	Biotechnology	Banks
Market Capitalization	413.22 billion USD	258.42 billion USD
Exchange	NYSE	NYSE
Listing Date	January 2, 2013	June 1, 1972
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of ABBV and WFC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. WFC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	ABBV	WFC
5-Day Price Return	4.82%	-4.70%
13-Week Price Return	23.58%	-3.50%
26-Week Price Return	11.64%	12.37%
52-Week Price Return	18.84%	45.88%
Month-to-Date Return	1.02%	-3.76%
Year-to-Date Return	31.63%	14.85%
10-Day Avg. Volume	6.76M	11.56M
3-Month Avg. Volume	5.66M	15.92M
3-Month Volatility	23.82%	24.11%
Beta	0.36	1.14

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

WFC

11.36%

Banks Industry

Max: 25.40%
Q3: 15.55%
Median: 12.00%
Q1: 8.98%
Min: -0.10%

WFC’s Return on Equity of 11.36% is on par with the norm for the Banks industry, indicating its profitability relative to shareholder equity is typical for the sector.

ABBV vs. WFC: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Banks industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

WFC

22.19%

Banks Industry

Max: 54.20%
Q3: 35.73%
Median: 28.97%
Q1: 22.56%
Min: 6.98%

Falling into the lower quartile for the Banks industry, WFC’s Net Profit Margin of 22.19% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.

ABBV vs. WFC: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Banks industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

WFC

25.35%

Banks Industry

Max: 63.35%
Q3: 44.73%
Median: 37.24%
Q1: 28.25%
Min: 12.28%

WFC’s Operating Profit Margin of 25.35% is in the lower quartile for the Banks industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

ABBV vs. WFC: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Banks industry benchmarks.

Profitability at a Glance

Symbol	ABBV	WFC
Return on Equity (TTM)	95.59%	11.36%
Return on Assets (TTM)	2.73%	1.06%
Net Profit Margin (TTM)	6.45%	22.19%
Operating Profit Margin (TTM)	18.80%	25.35%
Gross Profit Margin (TTM)	70.93%	--

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

WFC

Banks Industry

Max: --
Q3: --
Median: --
Q1: --
Min: --

For the Banks industry, the Current Ratio is often not the most suitable measure of short-term liquidity.

ABBV vs. WFC: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Banks industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

WFC

2.01

Banks Industry

Max: 5.78
Q3: 2.66
Median: 1.05
Q1: 0.40
Min: 0.00

The Debt-to-Equity Ratio is often not the primary focus for assessing leverage in the Banks industry.

ABBV vs. WFC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Banks industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

WFC

Banks Industry

Max: --
Q3: --
Median: --
Q1: --
Min: --

The Interest Coverage Ratio is often not a primary indicator of debt servicing capacity in the Banks industry.

ABBV vs. WFC: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Banks industry benchmarks.

Financial Strength at a Glance

Symbol	ABBV	WFC
Current Ratio (MRQ)	0.74	--
Quick Ratio (MRQ)	0.48	--
Debt-to-Equity Ratio (MRQ)	49.22	2.01
Interest Coverage Ratio (TTM)	2.70	--

Growth

Revenue Growth

ABBV vs. WFC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. WFC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

2.71%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABBV’s Dividend Yield of 2.71% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

WFC

2.47%

Banks Industry

Max: 11.03%
Q3: 6.00%
Median: 3.87%
Q1: 2.41%
Min: 0.00%

WFC’s Dividend Yield of 2.47% is consistent with its peers in the Banks industry, providing a dividend return that is standard for its sector.

ABBV vs. WFC: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Banks industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

WFC

31.00%

Banks Industry

Max: 134.24%
Q3: 79.39%
Median: 55.09%
Q1: 36.09%
Min: 0.00%

WFC’s Dividend Payout Ratio of 31.00% is in the lower quartile for the Banks industry. This suggests a conservative dividend policy, with a strategic focus on reinvesting profits for future growth.

ABBV vs. WFC: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Banks industry benchmarks.

Dividend at a Glance

Symbol	ABBV	WFC
Dividend Yield (TTM)	2.71%	2.47%
Dividend Payout Ratio (TTM)	226.84%	31.00%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

111.05

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

At 111.05, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

WFC

12.54

Banks Industry

Max: 22.69
Q3: 13.75
Median: 10.32
Q1: 7.73
Min: 2.59

WFC’s P/E Ratio of 12.54 is within the middle range for the Banks industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

ABBV vs. WFC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Banks industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

7.16

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

ABBV’s P/S Ratio of 7.16 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

WFC

1.91

Banks Industry

Max: 4.90
Q3: 2.98
Median: 2.24
Q1: 1.59
Min: 0.45

The P/S Ratio is often not a primary valuation tool in the Banks industry.

ABBV vs. WFC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Banks industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

WFC

1.42

Banks Industry

Max: 2.09
Q3: 1.40
Median: 1.11
Q1: 0.86
Min: 0.29

WFC’s P/B Ratio of 1.42 is in the upper tier for the Banks industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

ABBV vs. WFC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Banks industry benchmarks.

Valuation at a Glance

Symbol	ABBV	WFC
Price-to-Earnings Ratio (TTM)	111.05	12.54
Price-to-Sales Ratio (TTM)	7.16	1.91
Price-to-Book Ratio (MRQ)	261.01	1.42
Price-to-Free Cash Flow Ratio (TTM)	22.91	17.02